Molecular targeted therapy has a advance development, the molecular targeted therapies drug for epidermal growth factor receptor (EGFR) present definite clinic effect.

KRAS mutation frequency in tumor tissue, can be predicted non-small cell lung cancer molecular targeted therapy efficacy and prognosis, and molecular inhibitors of RAS genes is still in its infancy.

This article will summarize the new development of molecular targeted therapies currently in lung cancer.